Search research articles
Contact Us
Filters
Showing results (641-650 of 655) with videos related to
Page
of 66
Sort By:
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications
|
February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Lancet (London, England)
|
December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Arabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Nature Genetics
|
August 21, 2007
Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation
Patrick S Tarpey, F Lucy Raymond, Lam S Nguyen, et al.
The Journal of Infection
|
August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial
Leila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases
|
May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Alasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)
|
December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection
|
April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]
Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
Lancet (London, England)
|
December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
The Journal of Infection
|
April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Xinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Page
of 66
Search research articles
Search
Showing results (641-650 of 655) with videos related to
Sort By:
Page
of 66
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications
|
February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Lancet (London, England)
|
December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Arabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Nature Genetics
|
August 21, 2007
Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation
Patrick S Tarpey, F Lucy Raymond, Lam S Nguyen, et al.
The Journal of Infection
|
August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial
Leila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases
|
May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Alasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)
|
December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection
|
April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]
Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
Lancet (London, England)
|
December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
The Journal of Infection
|
April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Xinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Page
of 66